CT imaging phenotypes linked to CA125 and HE4 biomarkers are highly predictive in discriminating between hereditary and sporadic ovarian cancer patients.

Q3 Biochemistry, Genetics and Molecular Biology

Tumor Biology Pub Date : 2022-01-01 DOI:10.3233/TUB-211557

Lucia Manganaro, Veronica Celli, Valentina Viggiani, Elena Berardelli, Teresa Granato, Sara Tartaglione, Antonella Farina, Carlo Catalano, Antonio Angeloni, Emanuela Anastasi

{"title":"CT imaging phenotypes linked to CA125 and HE4 biomarkers are highly predictive in discriminating between hereditary and sporadic ovarian cancer patients.","authors":"Lucia Manganaro, Veronica Celli, Valentina Viggiani, Elena Berardelli, Teresa Granato, Sara Tartaglione, Antonella Farina, Carlo Catalano, Antonio Angeloni, Emanuela Anastasi","doi":"10.3233/TUB-211557","DOIUrl":null,"url":null,"abstract":"Background: Hereditary ovarian cancers (HOC) represent about 23% of ovarian cancer (OC) cases: they are most frequently related to germline mutations in the BRCA genes.Objective: We aimed to compare CA125/HE4 serum levels and Computed Tomography (CT) features at time of ovarian cancer (OC) diagnosis in two populations: BRCA mutant and BRCA wild-type (WT) OC, and to investigate the relationship between this laboratory and radiological biomarker and BRCA mutation status.Methods: This retrospective study included 60 newly diagnosed OC patients with FIGO stage IIIC-IV disease, tested for BRCA1/2 germline mutation status of which preoperative CT scan and serum tumor marker assay were available.Results: The median level of CA125 (708 U/mL) was significantly higher (p < 0.002) in BRCA1/2 mutated patients than in WT patients (176 U/mL), whereas the median level of HE4 (492 pmol/L) was significantly higher (p < 0.002) in WT than in BRCA-mutated patients (252 pmol/L). BRCA mutation carriers showed a higher incidence of bilateral ovarian masses (p = 0.0303) characterized by solid structures (p < 0.00001), higher peritoneal tumor load, macronodular implants >2 cm (p = 0.000099), increased frequency of lymphadenopathies (p = 0.019), and metastasis (p = 0.052) compared to patients with BRCA WT.Conclusions: Tumor markers and CT patterns may help in identifying BRCA mutation status in OC directing patients towards a personalized treatment.","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":"171-185"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumor Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/TUB-211557","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Hereditary ovarian cancers (HOC) represent about 23% of ovarian cancer (OC) cases: they are most frequently related to germline mutations in the BRCA genes.

Objective: We aimed to compare CA125/HE4 serum levels and Computed Tomography (CT) features at time of ovarian cancer (OC) diagnosis in two populations: BRCA mutant and BRCA wild-type (WT) OC, and to investigate the relationship between this laboratory and radiological biomarker and BRCA mutation status.

Methods: This retrospective study included 60 newly diagnosed OC patients with FIGO stage IIIC-IV disease, tested for BRCA1/2 germline mutation status of which preoperative CT scan and serum tumor marker assay were available.

Results: The median level of CA125 (708 U/mL) was significantly higher (p < 0.002) in BRCA1/2 mutated patients than in WT patients (176 U/mL), whereas the median level of HE4 (492 pmol/L) was significantly higher (p < 0.002) in WT than in BRCA-mutated patients (252 pmol/L). BRCA mutation carriers showed a higher incidence of bilateral ovarian masses (p = 0.0303) characterized by solid structures (p < 0.00001), higher peritoneal tumor load, macronodular implants >2 cm (p = 0.000099), increased frequency of lymphadenopathies (p = 0.019), and metastasis (p = 0.052) compared to patients with BRCA WT.

Conclusions: Tumor markers and CT patterns may help in identifying BRCA mutation status in OC directing patients towards a personalized treatment.

查看原文本刊更多论文

与CA125和HE4生物标志物相关的CT成像表型在区分遗传性和散发性卵巢癌患者方面具有很高的预测性。

背景:遗传性卵巢癌(HOC)约占卵巢癌(OC)病例的23%:它们最常与BRCA基因的种系突变有关。目的:比较两种人群(BRCA突变型和BRCA野生型(WT) OC)在卵巢癌(OC)诊断时的血清CA125/HE4水平和计算机断层扫描(CT)特征，并探讨该实验室和放射生物标志物与BRCA突变状态之间的关系。方法:本回顾性研究纳入60例新诊断的FIGO IIIC-IV期OC患者，检测其术前CT扫描和血清肿瘤标志物检测BRCA1/2种系突变状态。结果:与BRCA wt患者相比，CA125的中位水平(708 U/mL)显著升高(p 2 cm (p = 0.000099))，淋巴结病变(p = 0.019)和转移(p = 0.052)的频率增加。结论:肿瘤标志物和CT模式可能有助于识别OC中BRCA突变状态，指导患者进行个性化治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tumor Biology 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Tumor Biology is a peer reviewed, international journal providing an open access forum for experimental and clinical cancer research. Tumor Biology covers all aspects of tumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression. Specific topics of interest include, but are not limited to: Pathway analyses, Non-coding RNAs, Circulating tumor cells, Liquid biopsies, Exosomes, Epigenetics, Cancer stem cells, Tumor immunology and immunotherapy, Tumor microenvironment, Targeted therapies, Therapy resistance Cancer genetics, Cancer risk screening. Studies in other areas of basic, clinical and translational cancer research are also considered in order to promote connections and discoveries across different disciplines. The journal publishes original articles, reviews, commentaries and guidelines on tumor marker use. All submissions are subject to rigorous peer review and are selected on the basis of whether the research is sound and deserves publication. Tumor Biology is the Official Journal of the International Society of Oncology and BioMarkers (ISOBM).